Efficacy and safety of Jingqianshu granules in patients with premenstrual syndrome: a multicenter, randomized, double-blind, placebo-controlled trial
International Journal of Clinical Pharmacy · 2025
DOI: 10.1007/s11096-025-01949-5 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Clinical Pharmacy, 2025. Verfasst von Zhenzhen Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hebei University of Traditional Chinese Medicine, No. 326, Xinshi South Road, Qiaoxi District, Shijiazhuang, 050091, Hebei, China. Hauptthemen laut MEDLINE: Premenstrual Syndrome, Drugs, Chinese Herbal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Premenstrual syndrome (PMS) is a common disorder characterized by recurring somatic, emotional, and behavioral symptoms during the luteal phase of the menstrual cycle. Core manifestations include irritability, anxiety, insomnia, mood swings, breast tenderness, and headache. In Traditional Chinese Medicine (TCM), PMS with liver and qi stagnation is considered a pattern resulting from internal organ imbalance. Jingqianshu granules (JQS), a Chinese patented medicine, are traditionally used to soothe the liver, relieve depression, regulate qi, and alleviate pain. AIM: This study aimed to evaluate the clinical efficacy and safety of JQS in women with PMS characterized by liver stagnation and qi stagnation. METHOD: A total of 156 eligible participants were randomly assigned in a 2:1 ratio to receive JQS (n = 104) or placebo (n = 52) over three menstrual cycles, followed by a three-cycle post-treatment follow-up. The primary outcome was the change in the Daily Record of Severity of Problems (DRSP) scores. Secondary outcomes included TCM syndrome scores and improvements in individual symptoms. Safety was assessed by adverse event reporting and laboratory monitoring. RESULTS: The full analysis set (FAS) included 155 participants, and the per-protocol set (PPS) included 137. After three treatment cycles, DRSP scores were significantly reduced in the JQS group compared to placebo (FAS: - 14.3 ± 8.85 vs. - 10.1 ± 7.61; PPS: - 14.5 ± 8.61 vs. - 10.2 ± 7.13; both P 0.05), with no serious events reported. CONCLUSION: Jingqianshu granules significantly alleviated PMS symptoms and demonstrated good tolerability, supporting their use as a safe and effective treatment option for women with liver and qi stagnation-type PMS. TRIAL REGISTRATION: This trial was registered in the Chinese Clinical Trials Registry (ChiCTR2200058599).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hebei University of Traditional Chinese Medicine, No. 326, Xinshi South Road, Qiaoxi District, Shijiazhuang, 050091, Hebei, China.
- Anhui Provincial Hospital of Traditional Chinese Medicine, Hefei, 230000, China.
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.
- Feicheng Hospital of Shandong Yiyang Health Group, Shandong, 271600, China.
- Shandong Provincial Hospital of Traditional Chinese Medicine, Jinan, 250011, China.
- Qinhuangdao Shanhaiguan Pharmaceutical Co., Ltd., Qinhuangdao, 066200, China.
Zitieren
APA
Zhou, Z., Li, W., Liu, Y., Si, F., Wang, D., Sun, X., Song, N., Chen, W., & Du, H. (2025). Efficacy and safety of Jingqianshu granules in patients with premenstrual syndrome: a multicenter, randomized, double-blind, placebo-controlled trial. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-025-01949-5
Vancouver
Zhou Z, Li W, Liu Y, Si F, Wang D, Sun X, et al. Efficacy and safety of Jingqianshu granules in patients with premenstrual syndrome: a multicenter, randomized, double-blind, placebo-controlled trial. International Journal of Clinical Pharmacy. 2025. doi:10.1007/s11096-025-01949-5
BibTeX
@article{Zhou2025,
author = {Zhou, Zhenzhen and Li, Weili and Liu, Yanfeng and Si, Fujian and Wang, Dongmei and Sun, Xu and Song, Nan and Chen, Wenjing and Du, Huilan},
title = {Efficacy and safety of Jingqianshu granules in patients with premenstrual syndrome: a multicenter, randomized, double-blind, placebo-controlled trial},
journal = {International Journal of Clinical Pharmacy},
year = {2025},
doi = {10.1007/s11096-025-01949-5}
}
EUVIMED